The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Baseline tumor size as prognostic index in patients with cancer receiving experimental targeted agents.
 
Paolo Tarantino
Consulting or Advisory Role - AstraZeneca
 
Oriana D'Ecclesiis
No Relationships to Disclose
 
Eleonora Nicolò
No Relationships to Disclose
 
Gabriele Antonarelli
No Relationships to Disclose
 
Luca Boscolo Bielo
No Relationships to Disclose
 
Antonio Marra
No Relationships to Disclose
 
Sara Gandini
No Relationships to Disclose
 
Edoardo Crimini
No Relationships to Disclose
 
Federica Giugliano
No Relationships to Disclose
 
Paola Zagami
No Relationships to Disclose
 
Chiara Corti
No Relationships to Disclose
 
Dario Trapani
No Relationships to Disclose
 
Stefania Morganti
No Relationships to Disclose
 
Carmen Criscitiello
No Relationships to Disclose
 
Marzia Adelia Locatelli
No Relationships to Disclose
 
Carmen Belli
No Relationships to Disclose
 
Angela Esposito
No Relationships to Disclose
 
Ida Minchella
No Relationships to Disclose
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Giuseppe Curigliano
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Pfizer; Roche/Genentech